Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA PMA approval for Boston's Apex PCTA dilatation catheter

This article was originally published in Clinica

Executive Summary

Boston Scientific's Apex PCTA (percutaneous transluminal coronary angioplasty) dilatation catheter has received premarket approval (PMA) from the US FDA. It is designed for use during angioplasty and stenting procedures to open arteries blocked by complex atherosclerotic lesions, and is available on the Natick, Massachusetts firm's Monorail and Over-The-Wire catheter platforms. The catheter has a Bi-Segment inner shaft for "improved pushability and flexibility", Boston says. Balloon diameters of 1.5-5mm are available, with balloon lengths of 8-40mm (depending on diameter). There are two different 1.5mm designs – the Apex Push and Apex Flex catheters, the former for tight lesions and the latter for tortuous lesions. Boston CE marked the catheter for sale in Europe in October 2007 (see Clinica No 1276, p 18).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel